Eli Lilly reported positive top‑line Phase III results for retatrutide, a GIP/GLP‑1/glucagon ‘triple’ agonist, showing significant A1C reductions and substantial weight loss in people with type 2 diabetes after 40 weeks. The company said the therapy produced up to a 2.0% A1C drop on efficacy estimands and weight losses averaging over 16% at the highest doses. Lilly framed the data as establishing retatrutide’s potential in diabetes and as a stepping stone toward obesity indications. For readers: triple‑agonists target multiple metabolic hormone receptors to combine glycemic control and appetite suppression in one molecule. Regulatory pathways and safety monitoring will be pivotal next steps; Lilly emphasized tolerability profiles consistent with the GLP‑1 class, while flagging gastrointestinal adverse events and a small incidence of dysesthesia that will require follow‑up in safety dossiers.